ÂÌñÉç Pharma announces the successful completion of phase Ib with its FXR agonist EYP001 and the start of phase II studies in two indications, NASH and HBV
Lyon, November 06, 2018 – ÂÌñÉç Pharma, a clinical stage biotech company developing innovative drug candidates, today announced completion of its phase Ib clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of its FXR agonist compound EYP001 in patients with chronic hepatitis B virus infection (CHBV). The company highlights that EYP001 was well-tolerated by patients and induced a prolonged FXR target engagement after QD dosing over 4 weeks. ÂÌñÉç Pharma will now initiate two Phase II clinical trials of EYP001 in NASH and CHBV.
Read next in 'Press releases'
- ÂÌñÉç Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- ÂÌñÉç Pharma annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
- ÂÌñÉç Pharma annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1
- ÂÌñÉç Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- ÂÌñÉç Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
